Loading clinical trials...
Loading clinical trials...
The primary objective of this study is to demonstrate the efficacy of SR58611A 350 mg twice a day compared to placebo in elderly patients with Generalized Anxiety Disorder (GAD), as assessed by the 14...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Sanofi
NCT05569018 · Anxiety Disorders, Depressive Disorders
NCT06768749 · Sleep Problems, Depressive Disorder and Anxiety Disorders
NCT06066983 · Autism Spectrum Disorder, Anxiety Disorders
NCT06968026 · Recurrent Pregnancy Loss, Anxiety Disorders
NCT07174947 · Hepatobiliary Malignancy, Fluoxetine, and more
Sanofi-Aventis Administrative Office
Vienna
Sanofi-Aventis Administrative Office
Zagreb
Sanofi-Aventis Administrative Office
Helsinki
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions